2016


To access this material please log in or register

Register Authorize
2016/№3

Possibilities of indapamide for angioprotection in patients with metabolic syndrome following treatment with thiazide-containing combinations

Nedogoda S. V., Smirnova V. O., Khripaeva V. Yu., Palashkin R. V., Ledyaeva A. A., Chumachok E. V., Salasyuk A. S.
State Budgetary Educational Institution of Higher Professional Education, “Volgograd State Medical University” of the RF Ministry of Health Care, Ploshchad Pavshikh Boytsov 1, Volgograd 400131

Keywords: metabolic syndrome, indapamide, hydrochlorothiazide, adipokines, blood vessel elasticity

DOI: 10.18087/rhj.2016.3.2245

Aim. To evaluate the effect of replacing hydrochlorothiazide (HCT) with indapamide retard in combination with RAAS inhibitors on parameters of vascular compliance and inflammation in patients with metabolic syndrome. Materials and methods. This open, prospective, controlled study included 50 patients with metabolic syndrome (IDF, 2005) who had reached BP <140 / 90 mm Hg for three months of combination therapy with RAAS inhibitors + HCT (12.5 mg) and then were switched to the RAAS inhibitor, indapamide retard (1.5 mg), for 12 weeks. Metabolic parameters, blood levels of adipokines, and indexes of vascular compliance and vascular age were evaluated at the time of switching from the thiazide-containing combination to indapamide retard and at 12 weeks. Results. Switching patients with metabolic syndrome from the thiazide-containing combination therapy to the indapamide retard treatment slowed vascular ageing, improved vascular compliance, reduced inflammation, and exerted a beneficial effect on adipokine levels. Conclusion. Switching from the thiazide-containing combination therapy to the indapamide retard treatment additionally reduced BP, decreased insulin resistance and leptin, increased adiponectin, decreased hsCRP, improved indexes of large vessel compliance, and decreased vascular age.
  1. Niskanen L, Laaksonen DE, Nyyssönen K, Punnonen K, Valkonen VP, Fuentes R et al. Inflammation, abdominal obesity, and smo­king as predictors of hypertension. Hypertension. 2004 Dec;44 (6):859–65.
  2. Brasier AR, Recinos A, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002 Aug 1;22 (8):1257–66.
  3. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation. 2003 Dec 16;108 (24):2993–9.
  4. Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM. C-reactive protein and the risk of developing hypertension. JAMA. 2003 Dec 10;290 (22):2945–51.
  5. Mancia G, Fagard R, Narkiewicz К, Redon J, Zanchetti A, Bohm M et al. 2013 ESH / ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31 (7):1281–357 [Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH / ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31 (7):1281–357].
  6. Ridker PM, Danielson E, Rifai N, Glynn RJ. Valsartan, blood pressure reduction, and C-reactive protein primary report of the Val-MARC Trial. Hypertension. 2006 Jul;48 (1):73–9.
  7. Rahman ST, Lauten WB, Khan QA, Navalkar S, Parthasarathy S, Khan BV. Effects of eprosartan versus hydrochlorothiazide on markers of vascular oxidation and inflammation and blood pressure (renin-angiotensin system antagonists, oxidation, and inflammation). Am J Cardiol. 2002 Mar 15;89 (6):686–90.
  8. Fonseca FA, Ihara SS, Izar MC, Silva EP, Kasinski N, Lopes IE et al. Hydrochlorothiazide abolishes the anti‐atherosclerotic effect of quinapril. Clin Exp Pharmacol Physiol. 2003 Oct;30 (10):779–85.
  9. Чазова И. Е., Мычка В. Б. Окончательные результаты программы МИНОТАВР (пациенты с Метаболическим синдромом – эффективность и переносимость арифона ретард в лечении артериальной гипертонии). Consilium medicum. 2006;8 (11):11–5 [Chazova I. E., My`chka V. B. Okonchatel`ny`e rezul`taty` programmy` MINOTAVR (paczienty` s Metabolicheskim sindromom – e`ffektivnost` i perenosimost` arifona retard v lechenii arterial`noj gipertonii). Consilium medicum. 2006;8 (11):11–5].
  10. Недогода С. В. Диуретики при артериальной гипертензии: ангелы и демоны. Российский кардиологическиий журнал. 2013;3 (101):62–6 [Nedogoda S. V. Diuretiki pri arterial`noj gipertenzii: angely` i demony`. Rossiĭskiĭ kardiologicheskiĭ zhurnal. 2013;3 (101):62–6].
  11. Карпов Ю. А., Кисляк О. А., Недогода С. В., Деев А. Д. Основные результаты программы ОРИГИНАЛ. Кардиология. 2011;51 (3):36–41 [Karpov Yu. A., Kislyak O. A., Nedogoda S. V., Deev A. D. Osnovny`e rezul`taty` programmy` ORIGINAL. Kardiologiya. 2011;51 (3):36–41].
Nedogoda S. V., Smirnova V. O., Khripaeva V. Yu., Palashkin R. V., Ledyaeva A. A., Chumachok E. V. et al. Possibilities of indapamide for angioprotection in patients with metabolic syndrome following treatment with thiazide-containing combinations. Russian Heart Journal. 2016;15 (3):192–196

To access this material please log in or register

Register Authorize
Ru En